Prescription patterns following first-line new generation antidepressants for depression in Japan

A naturalistic cohort study based on a large claims database

Toshi A. Furukawa, Yoshie Onishi, Shiro Hinotsu, Aran Tajika, Nozomi Takeshima, Kiyomi Shinohara, Yusuke Ogawa, Yu Hayasaka, Koji Kawakami

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Several studies have described real-world prescription patterns of first-line antidepressants for depression but little is known about their fate in terms of duration, intensity and changes. Methods: An inception cohort of new onset non-psychotic depression initiating antidepressant treatment with a new generation antidpressive agent was identified in a large health insurance claims database in Japan between 2009 and 2010. The duration and intensity of first-line antidepressants, the timing and kind of second-line antidepressants and the total duration of antidepressant treatment were examined. Results: We identified 1592 patients. The starting dose and the maximum dose attained with the firstline agent appeared to be largely in line with the guideline recommendations although the latter tended toward the minimum of the recommended range. The continuity of the first-line antidepressant was far below the guideline recommendations, with 28%never returning after the initial prescription and 55%dropping out within 3 months. Of all the first-line antidepressants, 14%were subsequently augmented by another psychotropic agent while 17%were switched to another antidepressant after a median of 3 or 2 months, respectively. The choice of the second-line agents varied extremely widely. The total duration of antidepressant therapy was as short as a median of 4 months, with 68%stopping treatment by 6 months. Limitations: The diagnosis of non-psychotic unipolar depression in the claims database analyses remains approximate. Conclusions: The current guidelines are grossly out of touch with the clinical realities. On the one hand, guidelines need to reflect the real-world practices; on the other hand clinicians should limit their treatment options and allow evidence-based comparative effectiveness research among them so that patients shall no longer be given less effective and more effective treatments without being able to distinguish among them.

Original languageEnglish
Pages (from-to)916-922
Number of pages7
JournalJournal of Affective Disorders
Volume150
Issue number3
DOIs
Publication statusPublished - Sep 25 2013
Externally publishedYes

Fingerprint

Antidepressive Agents
Prescriptions
Japan
Cohort Studies
Databases
Depression
Guidelines
Therapeutics
Comparative Effectiveness Research
Insurance Claim Review
Touch
Health Insurance
Depressive Disorder

Keywords

  • Antidepressive agents
  • Depressive disorder
  • Drug administration schedule
  • Patient compliance

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Prescription patterns following first-line new generation antidepressants for depression in Japan : A naturalistic cohort study based on a large claims database. / Furukawa, Toshi A.; Onishi, Yoshie; Hinotsu, Shiro; Tajika, Aran; Takeshima, Nozomi; Shinohara, Kiyomi; Ogawa, Yusuke; Hayasaka, Yu; Kawakami, Koji.

In: Journal of Affective Disorders, Vol. 150, No. 3, 25.09.2013, p. 916-922.

Research output: Contribution to journalArticle

Furukawa, TA, Onishi, Y, Hinotsu, S, Tajika, A, Takeshima, N, Shinohara, K, Ogawa, Y, Hayasaka, Y & Kawakami, K 2013, 'Prescription patterns following first-line new generation antidepressants for depression in Japan: A naturalistic cohort study based on a large claims database', Journal of Affective Disorders, vol. 150, no. 3, pp. 916-922. https://doi.org/10.1016/j.jad.2013.05.015
Furukawa, Toshi A. ; Onishi, Yoshie ; Hinotsu, Shiro ; Tajika, Aran ; Takeshima, Nozomi ; Shinohara, Kiyomi ; Ogawa, Yusuke ; Hayasaka, Yu ; Kawakami, Koji. / Prescription patterns following first-line new generation antidepressants for depression in Japan : A naturalistic cohort study based on a large claims database. In: Journal of Affective Disorders. 2013 ; Vol. 150, No. 3. pp. 916-922.
@article{b0ca361a50d545dba88daa6b78358ae8,
title = "Prescription patterns following first-line new generation antidepressants for depression in Japan: A naturalistic cohort study based on a large claims database",
abstract = "Background: Several studies have described real-world prescription patterns of first-line antidepressants for depression but little is known about their fate in terms of duration, intensity and changes. Methods: An inception cohort of new onset non-psychotic depression initiating antidepressant treatment with a new generation antidpressive agent was identified in a large health insurance claims database in Japan between 2009 and 2010. The duration and intensity of first-line antidepressants, the timing and kind of second-line antidepressants and the total duration of antidepressant treatment were examined. Results: We identified 1592 patients. The starting dose and the maximum dose attained with the firstline agent appeared to be largely in line with the guideline recommendations although the latter tended toward the minimum of the recommended range. The continuity of the first-line antidepressant was far below the guideline recommendations, with 28{\%}never returning after the initial prescription and 55{\%}dropping out within 3 months. Of all the first-line antidepressants, 14{\%}were subsequently augmented by another psychotropic agent while 17{\%}were switched to another antidepressant after a median of 3 or 2 months, respectively. The choice of the second-line agents varied extremely widely. The total duration of antidepressant therapy was as short as a median of 4 months, with 68{\%}stopping treatment by 6 months. Limitations: The diagnosis of non-psychotic unipolar depression in the claims database analyses remains approximate. Conclusions: The current guidelines are grossly out of touch with the clinical realities. On the one hand, guidelines need to reflect the real-world practices; on the other hand clinicians should limit their treatment options and allow evidence-based comparative effectiveness research among them so that patients shall no longer be given less effective and more effective treatments without being able to distinguish among them.",
keywords = "Antidepressive agents, Depressive disorder, Drug administration schedule, Patient compliance",
author = "Furukawa, {Toshi A.} and Yoshie Onishi and Shiro Hinotsu and Aran Tajika and Nozomi Takeshima and Kiyomi Shinohara and Yusuke Ogawa and Yu Hayasaka and Koji Kawakami",
year = "2013",
month = "9",
day = "25",
doi = "10.1016/j.jad.2013.05.015",
language = "English",
volume = "150",
pages = "916--922",
journal = "Journal of Affective Disorders",
issn = "0165-0327",
publisher = "Elsevier",
number = "3",

}

TY - JOUR

T1 - Prescription patterns following first-line new generation antidepressants for depression in Japan

T2 - A naturalistic cohort study based on a large claims database

AU - Furukawa, Toshi A.

AU - Onishi, Yoshie

AU - Hinotsu, Shiro

AU - Tajika, Aran

AU - Takeshima, Nozomi

AU - Shinohara, Kiyomi

AU - Ogawa, Yusuke

AU - Hayasaka, Yu

AU - Kawakami, Koji

PY - 2013/9/25

Y1 - 2013/9/25

N2 - Background: Several studies have described real-world prescription patterns of first-line antidepressants for depression but little is known about their fate in terms of duration, intensity and changes. Methods: An inception cohort of new onset non-psychotic depression initiating antidepressant treatment with a new generation antidpressive agent was identified in a large health insurance claims database in Japan between 2009 and 2010. The duration and intensity of first-line antidepressants, the timing and kind of second-line antidepressants and the total duration of antidepressant treatment were examined. Results: We identified 1592 patients. The starting dose and the maximum dose attained with the firstline agent appeared to be largely in line with the guideline recommendations although the latter tended toward the minimum of the recommended range. The continuity of the first-line antidepressant was far below the guideline recommendations, with 28%never returning after the initial prescription and 55%dropping out within 3 months. Of all the first-line antidepressants, 14%were subsequently augmented by another psychotropic agent while 17%were switched to another antidepressant after a median of 3 or 2 months, respectively. The choice of the second-line agents varied extremely widely. The total duration of antidepressant therapy was as short as a median of 4 months, with 68%stopping treatment by 6 months. Limitations: The diagnosis of non-psychotic unipolar depression in the claims database analyses remains approximate. Conclusions: The current guidelines are grossly out of touch with the clinical realities. On the one hand, guidelines need to reflect the real-world practices; on the other hand clinicians should limit their treatment options and allow evidence-based comparative effectiveness research among them so that patients shall no longer be given less effective and more effective treatments without being able to distinguish among them.

AB - Background: Several studies have described real-world prescription patterns of first-line antidepressants for depression but little is known about their fate in terms of duration, intensity and changes. Methods: An inception cohort of new onset non-psychotic depression initiating antidepressant treatment with a new generation antidpressive agent was identified in a large health insurance claims database in Japan between 2009 and 2010. The duration and intensity of first-line antidepressants, the timing and kind of second-line antidepressants and the total duration of antidepressant treatment were examined. Results: We identified 1592 patients. The starting dose and the maximum dose attained with the firstline agent appeared to be largely in line with the guideline recommendations although the latter tended toward the minimum of the recommended range. The continuity of the first-line antidepressant was far below the guideline recommendations, with 28%never returning after the initial prescription and 55%dropping out within 3 months. Of all the first-line antidepressants, 14%were subsequently augmented by another psychotropic agent while 17%were switched to another antidepressant after a median of 3 or 2 months, respectively. The choice of the second-line agents varied extremely widely. The total duration of antidepressant therapy was as short as a median of 4 months, with 68%stopping treatment by 6 months. Limitations: The diagnosis of non-psychotic unipolar depression in the claims database analyses remains approximate. Conclusions: The current guidelines are grossly out of touch with the clinical realities. On the one hand, guidelines need to reflect the real-world practices; on the other hand clinicians should limit their treatment options and allow evidence-based comparative effectiveness research among them so that patients shall no longer be given less effective and more effective treatments without being able to distinguish among them.

KW - Antidepressive agents

KW - Depressive disorder

KW - Drug administration schedule

KW - Patient compliance

UR - http://www.scopus.com/inward/record.url?scp=84888359803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888359803&partnerID=8YFLogxK

U2 - 10.1016/j.jad.2013.05.015

DO - 10.1016/j.jad.2013.05.015

M3 - Article

VL - 150

SP - 916

EP - 922

JO - Journal of Affective Disorders

JF - Journal of Affective Disorders

SN - 0165-0327

IS - 3

ER -